| 77.3593 1.539 (2.03%) | 07-16 10:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 96.07 | 1-year : | 112.22 |
| Resists | First : | 82.26 | Second : | 96.07 |
| Pivot price | 77.42  |
|||
| Supports | First : | 72.84 | Second : | 67.01 |
| MAs | MA(5) : | 76.1  |
MA(20) : | 75.41 |
| MA(100) : | 68.69 |
MA(250) : | 69.08 |
|
| MACD | MACD : | 1.8 |
Signal : | 2.1 |
| %K %D | K(14,3) : | 49.7 |
D(3) : | 51.3 |
| RSI | RSI(14): 58 |
|||
| 52-week | High : | 82.26 | Low : | 55.63 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ HALO ] has closed above bottom band by 49.1%. Bollinger Bands are 4.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 76.3 - 76.81 | 76.81 - 77.26 |
| Low: | 72.64 - 73.29 | 73.29 - 73.87 |
| Close: | 74.82 - 75.84 | 75.84 - 76.76 |
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.
Wed, 15 Jul 2026
Halozyne Therapeutics (HALO) Is An Undervalued Stock That Keeps Winning In Cancer Treatment - Yahoo Finance
Mon, 13 Jul 2026
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Unveiling a 10% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Sat, 11 Jul 2026
Halozyme Therapeutics (HALO) Q1 2025 earnings summary - Quartr
Sat, 11 Jul 2026
Halozyme Therapeutics (HALO) Proxy filing Summary - Quartr
Sat, 11 Jul 2026
Halozyme Therapeutics (HALO) AGM 2026 Summary - Quartr
Fri, 10 Jul 2026
2 Reasons to Like HALO and 1 to Stay Skeptical - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 119 (M) |
| Shares Float | 117 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 108.3 (%) |
| Shares Short | 13,230 (K) |
| Shares Short P.Month | 13,640 (K) |
| EPS | 2.84 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.85 |
| Profit Margin | 23.1 % |
| Operating Margin | 48.9 % |
| Return on Assets (ttm) | 22 % |
| Return on Equity (ttm) | 99.4 % |
| Qtrly Rev. Growth | 42.2 % |
| Gross Profit (p.s.) | 9.77 |
| Sales Per Share | 12.73 |
| EBITDA (p.s.) | 8.03 |
| Qtrly Earnings Growth | 31.2 % |
| Operating Cash Flow | 677 (M) |
| Levered Free Cash Flow | 228 (M) |
| PE Ratio | 27.13 |
| PEG Ratio | 0 |
| Price to Book value | 41.8 |
| Price to Sales | 6.07 |
| Price to Cash Flow | 13.54 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|